– UK, Nottingham – Scancell Holdings plc (LON: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announced the appointment of the founder, Board Director, and CSO, Professor Lindy Durrant as CEO with immediate effect.
“As a founder and CSO, Lindy is the driving force behind Scancell’s internationally recognised science. The Board firmly believes her strategic insight and commitment to moving products into the clinic as well as her strong leadership skills will deliver significant value to the business and to shareholders.” said Executive Chairman, Dr John Chiplin.
Professor Durrant was previously co-CEO of the Company. Dr. Cliff Holloway has decided to step down as a Board Director and CEO, with immediate effect.
Professor Lindy Durrant said: “I believe Scancell has an unrivaled pipeline of products and I, along with the rest of the team at Scancell, intend to continue to drive our pipeline through the clinic as we focus on accelerating the development of what we believe to be our most commercially promising assets.”
Dr. Cliff Holloway said: “Since I joined Scancell in early 2018 we’ve built and financed the Company to the point where it has a strong and diverse pipeline and it can now embark on its next phase of growth. I’m proud to have led Scancell during this pivotal time. The Company is now stronger than ever and I look forward to following its continued progress.”
Scancell is developing novel immunotherapies for the treatment of cancer based on its technology platforms, ImmunoBody, Moditope, and AvidiMab, with four products in multiple cancer indications and the development of a vaccine for COVID-19.
ImmunoBody vaccines target dendritic cells and stimulate both CD4 and CD8 T cells with the ability to identify, target, and eliminate cancer cells. These cancer vaccines have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. The Directors believe that this platform has the potential to enhance tumor destruction, prevent disease recurrence and extend survival.
- SCIB1, Scancell’s lead product, is being developed for the treatment of metastatic melanoma. In a Phase 1/2 clinical trial, survival with SCIB1 treatment appears superior to historical survival rates, with 14 of 16 resected patients receiving 2-4 mg doses of SCIB1 surviving for more than five years.
- SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumors.
DNA vaccine against COVID-19: As research data emerge, it is becoming increasingly clear that the induction of potent and activated T cells play a critical role in the development of long-term immunity and clearance of virus-infected cells. Initial research is underway and Scancell anticipates initiating a Phase 1 clinical trial known as COVIDITY during 2021.
For more information: https://www.scancell.co.uk
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.